An expert spoke with CURE® about the importance of information that can be gained from genetic testing for patients with ...

When we got back from the beach, fall was in the air, and we both were back in the reality of doctor appointments, CT scans, ...

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on ...

CURE® highlights some of the top stories from SABCS, including those focused on older and younger patients with breast cancer ...

With breakthroughs from melanoma to pancreatic cancer, this has been a year of great promise in the field of cancer vaccines.

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory ...

This Christmas, my wish for all of you is that you read this and feel seen, that someone out there knows how very hard this ...

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

In February 2024, the FDA approved Onivyde (irinotecan liposome) with oxaliplatin, fluorouracil and leucovorin for the ...

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated ...

One of this year’s MPN Heroes® talked about the importance of a supportive care team, especially as every patient with MPN ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...